FIG 1.

vMC₂₄ has oncolytic activity against a broad range of cancer cell lines and exhibits potent oncolytic activity in vivo, but it causes lethal toxicity. (A) Cytotoxicity of vMC₂₄ against a panel of human and murine cancer cell lines. Data are presented as mean percent cell viability relative to that of mock-infected cells at 72 h postinfection from duplicate or triplicate experiments ± standard deviations. (B and C) BALB/c mice bearing s.c. MPC-11 tumors were treated with a single injection of vMC₂₄ i.v. (1 × 10⁷ TCID₅₀) (B) or i.t. (1 × 10⁶ TCID₅₀) (C), and tumor burden was monitored by calculating tumor volume versus time using repeated caliper measurements. Overall survival of control Opti-MEM-treated and vMC₂₄-treated mice was assessed using Kaplan-Meier survival curves. The tabulation of the causes of death/euthanasia other than tumor burden in all treated mice, median survival, and significance of overall survival benefit in vMC₂₄-treated mice versus control mice based on log-rank statistics are shown.